No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data

AIMS: Despite patient reports of neurocognitive disorders with lipid-lowering treatments (LLTs), large clinical trials have found no significant association between neurocognitive disorders and LLTs. We assessed incidence of neurocognitive treatment-emergent adverse events (TEAEs) from 14 Phase 2 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Harvey, Philip D, Sabbagh, Marwan N, Harrison, John E, Ginsberg, Henry N, Chapman, M John, Manvelian, Garen, Moryusef, Angele, Mandel, Jonas, Farnier, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837381/
https://www.ncbi.nlm.nih.gov/pubmed/29186504
http://dx.doi.org/10.1093/eurheartj/ehx661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837381/
https://www.ncbi.nlm.nih.gov/pubmed/29186504
http://dx.doi.org/10.1093/eurheartj/ehx661

Ejemplares similares